Company description

GVK BIO is a global Contract Research & Development Organization (CRDO) providing Drug Discovery and Development services to the biopharma industry. Established in 2001, GVK BIO for over 18 years has supported the Research and Development programs of innovator drug companies enabling them to bring their products to market quicker and cost- effectively.

We are a team of over 2100 highly qualified scientists, backed by well-defined and scalable processes, modern facilities and a strong customer-centric partnering approach. Our distinctiveness comes from our expertise in the breadth and depth of services that we provide in drug discovery and development. We recognize that our clients’ needs are diverse, and we have designed our services accordingly. GVK BIO’s capabilities include Integrated Drug Discovery, Chemistry, Biology, Large molecule R&D , Chemical Development, Formulation & Analytical development, Contract Manufacturing and Drug Repurposing.

Spread across 55 acres of land, GVK BIO has five state-of-the-art research facilities, four in India and one in Morgan Hill, California. All our facilities confirm to stringent regulatory standards. Our infrastructure has a built-up area of 1,200,000 square feet, housing chemistry & biology labs, AAALAC accredited animal house, analytical labs, formulation development labs, kilo labs, pilot plants and manufacturing facilities. GVK BIO has been inspected by all the leading regulatory agencies of the world including USFDA, WHO, PMDA, EDQM and EMEA.

In 2014, GVK BIO acquired Aragen Bioscience, Inc., a US-based preclinical CRO specializing in biologics services, thereby enabling clients access an integrated R&D services platform across both large and small molecules.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Analytical Chemistry |Analytical Development |Analytical Methods More

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 120C91 See our Exhibitor Profile   See full Exhibitor List

News about GVK BIO

Biological E and GVK BIO announce strategic R&D Partnership

27 Aug 2019

Biological E and GVK BIO announce strategic R&D Partnership

GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and BE Pharmaceuticals Inc (BE Inc), a rapidly growing pharmaceutical company that develops, manufactures and markets complex and critical injectable products, announced a strategic collaboration in drug product development.

Read more

27 Aug 2019

GVK BIO Announces USFDA Approval for its cGMP Analytical Services Laboratory

July 10, 2019, Hyderabad, India: GVK BIO is pleased to announce the appointment of Dr. Robert (Bob) R. Ruffolo, to its Board of Directors.

Read more

27 Aug 2019

GVK BIO announces the appointment of Axel Schleyer, Ph.D. as CEO of Aragen Bioscience

GVK BIO is pleased to announce the appointment of Dr. Axel Schleyer as Chief Executive Officer, of Aragen Bioscience Inc.

Read more

26 Aug 2019

LifeArc And GVK BIO Celebrate A Decade Of Partnership, Transforming Research Into Life-Saving Medicines

GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, are pleased to announce the 10th anniversary of a successful partnership.

Read more

Contact information




View all contact information